Last reviewed · How we verify
Discontinuation of β-blocker — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Discontinuation of β-blocker (Discontinuation of β-blocker) — Samsung Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Discontinuation of β-blocker TARGET | Discontinuation of β-blocker | Samsung Medical Center | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Discontinuation of β-blocker CI watch — RSS
- Discontinuation of β-blocker CI watch — Atom
- Discontinuation of β-blocker CI watch — JSON
- Discontinuation of β-blocker alone — RSS
Cite this brief
Drug Landscape (2026). Discontinuation of β-blocker — Competitive Intelligence Brief. https://druglandscape.com/ci/discontinuation-of-blocker. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab